Exact Sciences Corporation (NASDAQ:EXAS) Stock Holdings Lifted by Beech Hill Advisors Inc.

Beech Hill Advisors Inc. lifted its position in Exact Sciences Corporation (NASDAQ:EXAS - Free Report) by 29.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 59,911 shares of the medical research company's stock after purchasing an additional 13,476 shares during the quarter. Beech Hill Advisors Inc.'s holdings in Exact Sciences were worth $2,594,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in EXAS. Goldstein Advisors LLC boosted its position in shares of Exact Sciences by 113.8% during the first quarter. Goldstein Advisors LLC now owns 12,254 shares of the medical research company's stock valued at $530,000 after buying an additional 6,523 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in shares of Exact Sciences by 298.6% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 148,629 shares of the medical research company's stock worth $6,434,000 after purchasing an additional 111,343 shares during the last quarter. Global Assets Advisory LLC purchased a new stake in Exact Sciences in the first quarter valued at about $280,000. FORM Wealth Advisors LLC purchased a new stake in Exact Sciences in the first quarter valued at about $342,000. Finally, Asset Management One Co. Ltd. raised its stake in shares of Exact Sciences by 4.5% in the first quarter. Asset Management One Co. Ltd. now owns 68,500 shares of the medical research company's stock worth $2,965,000 after purchasing an additional 2,949 shares during the last quarter. 88.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently commented on EXAS. Barclays dropped their target price on Exact Sciences from $75.00 to $65.00 and set an "overweight" rating on the stock in a report on Tuesday. Evercore ISI raised their price objective on Exact Sciences from $60.00 to $66.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Mizuho initiated coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price objective on the stock. Robert W. Baird raised their price objective on Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, Royal Bank Of Canada raised their price objective on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Exact Sciences presently has an average rating of "Moderate Buy" and an average price target of $70.40.

Insiders Place Their Bets

In other news, Director Katherine S. Zanotti sold 3,207 shares of the business's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total value of $170,612.40. Following the sale, the director now owns 72,759 shares of the company's stock, valued at approximately $3,870,778.80. The trade was a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Exact Sciences Stock Up 3.6%

NASDAQ:EXAS traded up $1.84 during mid-day trading on Friday, hitting $53.65. The company had a trading volume of 9,017,373 shares, compared to its average volume of 2,577,911. The business has a fifty day simple moving average of $52.83 and a 200-day simple moving average of $51.51. The company has a current ratio of 2.73, a quick ratio of 2.38 and a debt-to-equity ratio of 0.97. Exact Sciences Corporation has a 1 year low of $39.97 and a 1 year high of $72.83. The firm has a market capitalization of $10.12 billion, a price-to-earnings ratio of -9.74, a PEG ratio of 39.33 and a beta of 0.98.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.16. The company had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. Exact Sciences had a negative return on equity of 3.75% and a negative net margin of 36.06%. The company's revenue was up 10.9% on a year-over-year basis. During the same period last year, the firm earned ($0.60) earnings per share. Equities analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.